Top Stories
-
Columbia’s Dian Yang is placing CRISPR-based molecular recorders into cancer cells to eavesdrop on cancer evolution and pinpoint when and how cells metastasize.
Topic
-
Misinformation and outdated beliefs about screening tests, treatment options, and effects on sexual health continue to cloud understanding about this disease.
Topic
-
The Columbia community gathered in the Hudson Valley for the eighth annual Velocity: Columbia’s Ride to End Cancer. This year’s event raised more than $1 million and attracted nearly 600 participants.
Topic
-
Columbia researchers have engineered bacteria as personalized cancer vaccines that activate the immune system to specifically seek out and destroy cancer cells.
Topic
Latest News
- September 18, 2015
Dr. Naiyer Rizvi, director of thoracic oncology at CUMC, offers updates on immune checkpoint inhibitors in certain forms of lung cancers.
Topic
- May 26, 2015
Columbia scientists have created new decoy drugs that can intercept the deceptive growth signals that cancer cells send out.
- April 14, 2015
A study of the genomes of patients with a particularly aggressive form of non-Hodgkin’s lymphoma shows that many cases are driven by alterations in the JAK/STAT3 cell signaling pathway.
- March 26, 2015
Nearly 50 years after the “war on cancer” was declared in the United States, precision medicine is changing the face of cancer research.
Topic
- March 19, 2015
At a special event at Columbia, oncologists and scientists will discuss how new research is changing the way cancer is being treated.
Topic
- March 16, 2015
At Columbia, every pediatric cancer patient’s tumor is sequenced, so personalized treatment may be considered.
Topic
- March 12, 2015
Advances in how the immune system can be harnessed to fight cancer offer new hope to patients with lung cancer.
Topic
- February 26, 2015
Director of the National Cancer Institute, Harold Varmus, MD'66, talked about the challenges and goals of precision medicine's efforts to tackle cancer.
Topic
- February 23, 2015
Household net worth is a major and overlooked factor in adherence to hormonal therapy among breast cancer patients and partially explains racial disparities in quality of care.
Topic
